LamD Inhibits Topoisomerase Activity: A Potential Target for Anti-Cancer Drugs

Researchers have discovered that LamD, a promising anti-cancer drug candidate, inhibits the activity of topoisomerase enzymes through a unique mechanism. They observed that the carbonyl group on the LamD inner lipid ring, along with the hydroxyl groups on C-8 and C-20, interact with three key binding sites (Arg 364, Asn 722, Glu 356) within the Topo I binding pocket, forming a ternary complex. This interaction strengthens the binding of Topo I to the DNA-LamD complex, boosting its ability to cleave and re-ligate the DNA strand.

Furthermore, the researchers found that LamD can also inhibit the activity of Topo II, another type of topoisomerase enzyme crucial for DNA replication and transcription. LamD binds to the ATPase domain of Topo II, preventing it from hydrolyzing ATP and hindering the enzyme from completing its catalytic cycle.

These findings strongly suggest that LamD employs a distinct mechanism in inhibiting topoisomerase enzymes. This unique action presents a promising avenue for the development of novel anti-cancer drugs. However, further research is essential to thoroughly understand the molecular details of LamD's interactions with topoisomerases and its potential therapeutic applications.